Co -incubation of a replication -deficient, recombinant adenovirus carrying the wild -type p53 gene ( rAd -p53 ) and hematopoietic stem cell ( HSC ) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient ( SCID ) mice and to undergo secondary transplantation provides the only nonclinical measure of self -renewing, stem cell function. The objective of this study was to investigate whether co -incubation with rAd -p53 compromised the SCID repopulating activity ( SRA ) of HSC. Granulocyte colonystimulating factor -mobilized human CD34 + cells were co -cultured with rAd -p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic ( NOD ) -SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte -macrophage colony -forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34 + cells co -incubated with rAd -p53 and control CD34 + cells ( no rAd -p53 co -incubation ) . We conclude that co -incubation with rAd -p53 has little effect on the SRA of HSC. Cancer Gene Therapy ( 2001 ) 8, 936 -947
H ematopoietic stem cell (HSC ) transplantation has allowed the use of more aggressive, high -dose therapy ( HDT ) regimens in the treatment of breast cancer. 1 -3 Whereas this approach may significantly increase the response rate, the harvest of HSC from the bone marrow, or from the blood of cytokine-mobilized patients, may be problematic if the stem cell product is contaminated with tumor cells. In patients with localized or advanced breast cancer, tumor cells are often detected in the harvested stem cell product. 4 -8 Tumor cell contamination of the transplanted stem cell product is a significant prognostic variable for relapse-free and overall survival, 9 and is associated with cancer recurrence. 10 Therefore, strategies to purge tumor cells from the stem cell product may significantly improve the outcome for breast cancer patients undergoing HDT and HSC transplantation. Several novel strategies have been developed to reduce tumor cell contamination of stem cell products including CD34 + cell enrichment, 11 targeted monoclonal antibodies, 12 and adenovirus -delivered gene therapy. 13 -24 The therapeutic utility of purging in breast cancer was recently supported by a phase III study demonstrating a significant prolongation of time to relapse in stage II /IIIa breast cancer patients, whose stem cell product was purged by CD34 + cell isolation, resulting in a 254 -fold reduction of tumor cells. 25 A number of features make the use of adenovirusdelivered gene therapy attractive for the purging of tumor cells from stem cell products. A recombinant adenovirus carrying the LacZ reporter gene was shown to be approximately 4000 -fold more effective at transfecting breast cancer cells than hematopoietic cells. 17 Further, a replication -deficient, recombinant adenovirus encoding wild -type p53 (rAd -p53) could efficiently purge tumor cells from stem cell products. 17 Indeed, the co-incubation of tumor cell -contaminated stem cell products with rAd -p53 reduced tumor cell numbers by six logs. 18, 24 The efficacy of this strategy is underscored by the observation that in addition to preferential transduction, the target replacement gene, p53, is mutated in over 50% of breast cancer patients Whereas previous studies have shown that the coincubation of stem cell products with rAd -p53 does not impact in vitro hematopoietic progenitor cell function, 27, 28 these findings do not address the sequelae of rAd -p53 co -incubation on the primitive HSC compartment critical for successful HSC transplantation. A murine model [ nonobese diabetic /severe combined immunodeficient ( NOD -SCID ) mouse] , which allows such studies, 29, 30 has been developed. When human HSCs are injected intravenously into sublethally irradiated SCID or NOD -SCID mice, they engraft, and human -derived cells (myeloid, lymphoid, erythroid, and megakaryocyte ) are detectable for several months posttransplantation without the addition of human hematopoietic growth factors. 31, 32 Further, serial transplantation of the mouse-human chimeric marrow cells to sublethally irradiated, NOD -SCID recipients demonstrates the self -renewing, multipotential nature of human -derived NOD -SCID repopulating cells. 32 Thus, NOD -SCID mice provide an effective model with which to investigate the impact of a purging protocol on the critical HSC compartment. In addition, the incorporation of a limiting dilution analysis (LDA ) provides a sensitive, quantitative measure of long -term NOD -SCID repopulating activity. Here we report the use of LDA to compare the SRA of CD34 + cells co -incubated with rAdp53 to that of CD34 + cells incubated with medium alone. We report that rAd -p53 co-incubation with human CD34 + cells, using clinically relevant parameters, was without significant effect on SRA, and supports the use of this strategy to purge tumor cells from stem cell products.
MATERIALS AND METHODS

Recombinant adenovirus
Replication -deficient adenovirus particles encoding human p53 ( rAd -p53 ) were provided by the Schering-Plough Research Institute ( Kenilworth, NJ ) and prepared, purified, and titered as previously described. 33 The E1a and E1b regions of the human type 5 adenovirus were replaced with the human p53 gene under the transcriptional control of the cytomegalovirus promoter. The rAd -p53 particles were produced in the human embryonic kidney cell line 293 and purified by column chromatography. Virus particles were quantified using analytical anion exchange and high -pressure liquid chromatography. 34 This technique of quantitation, based on particle numbers, has been recommended by the Food and Drug Administration. 35 Once quantified, rAd -p53 particles were stored in a Tris phosphate buffer containing 2 mM MgCl 2 and 10% glycerol at À 708C until required.
Isolation of CD34
+ cells from granulocyte colony -stimulating factor ( G -CSF ) -mobilized blood Three patients with non -Hodgkin's lymphoma received G -CSF ( Filgrastim Neupogen; Immunex, Seattle, WA ) according to a University of Nebraska Medical Center stem cell mobilization protocol developed for autologous transplantation. Each sample was freshly drawn and only one sample was processed at a time. Identical procedures were followed for each of the three samples. Red blood cells were removed using ammonium chloride lysis and mononuclear cells isolated over a Ficoll -Hypaque gradient. Isolated cells were washed and counted using a Serono -Baker System 9000 Hematology Series Cell Counter (Serono -Baker Diagnostic, Allentown, PA ). Mononuclear cell numbers were adjusted for optimal CD34 + cell selection using colloidal, superparamagnetic MACS MicroBeads conjugated with an anti -CD34 antibody as per manufacturer's instructions ( CD34 Progenitor Cell Isolation Kit; Miltenyi Biotech, Auburn, CA ) . In these studies, we performed the Miltenyi CD34 + cell column selection procedure only once for each G -CSF -mobilized blood sample. This yielded 73%, 99%, and 49% CD34 + purity. + cells ). Five and 11 days after transplantation, mice again received antiasialo GM1 antibody. Six weeks after transplantation, mice were euthanized, and for each mouse, a single cell suspension of femoral marrow cells was collected into cold Iscove's modified Dulbecco's medium (IMDM; GibcoBRL, Grand Island, NY ) with 10% ( v/ v) fetal bovine serum ( FBS; Sigma, St. Louis, MO ) . The presence of human -derived progenitor cells in the marrow of NOD -SCID mice was investigated using three different techniques: (a) in vitro colony -forming cell assay, ( b ) flow cytometry, and (c ) DNA extraction and Southern blot analysis.
Co -incubation of CD34
+ cells with rAd -p53 particles Isolated human CD34 + cells (purity determined by flow cytometry ) were divided into two equal aliquots (3Â10 Because the purity of the CD34 + cells varied between samples, the total number of cells co -incubated was corrected such that the number of CD34 + cells was identical between samples. One aliquot was incubated in a total volume of 250 L of IMDM with 10% FBS containing 5Â10 10 rAd -p53 particles (final rAd -p53 concentration of 2Â10 11 rAd -p53 particles /mL ); the other aliquot was incubated in 250 L of IMDM with 10% FBS containing no virus particles ( control ). Samples were incubated for 4 hours at 378C. After incubation, 2 mL of IMDM with 10% FBS was added and cell numbers determined for subsequent granulocyte -macrophage colony -forming unit ( CFU -GM ) assay to measure acute toxicity of coincubation with rAd -p53 and for transplantation into sublethally irradiated NOD -SCID mice.
In vitro CFU -GM assay of human -derived hematopoietic colony -forming cells 
Flow cytometry
Marrow from each of the NOD -SCID mice was analyzed for the presence of human cells. Approximately 1Â10 6 marrow cells were suspended in Dulbecco's phosphate -buffered saline (DPBS ) containing 2% ( v/ v) FBS (DPBS-2% FBS ) and kept cold throughout the assays. Red blood cells were removed by ammonium chloride lysis and nucleated cells pelleted by centrifugation. Cells were incubated ( + 48C, 20 minutes ) in 1 mL of -globulin ( 1 mg /mL ) to block nonspecific binding of antibodies.
A range of human -specific cell markers were analyzed. Human-derived lymphopoiesis in the mice was followed by the expression of CD8 ( cytotoxic /suppressor T lymphocyte ), CD19 (pan B lymphocyte ), CD38 (plasma cells, thymocytes, and activated T lymphocytes), and CD56 ( NK cells) . Human -derived myelopoiesis was followed by the expression of CD13 (myeloid, monocyte, and granulocyte ) and CD14 (monocytes, some granulocytes, and macrophages). Human-derived erythropoiesis and megakaryocytopoiesis were followed by the expression of glycophorin A + cells, NOD -SCID bone marrow was isolated and evidence of human -derived cells sought by in vitro colony -forming cell ( CFU -GM ) assay using species -specific colony -stimulating factors ( rhuIL -3 and rhuGM -CFC ) . Data are presented as frequency of CFU -GM / 10 6 marrow cells. In marrow from NOD -SCID mice transplanted with lethally irradiated ( 15 Gy ) human marrow cells, a background of 6 ± 1 CFU -GM / 10 6 marrow cells plated was observed. In all cases, the number of CFU -GM detected in mice receiving rAd -p53 co -incubated, or control CD34 + cells, was significantly greater than ( P .05 ) that seen in mice receiving the lethally irradiated human ''carrier'' cells alone ( receiving no rAd -p53 co -incubated or control CD34 + cells ) . Data presented as mean ± SEM, n = 5 mice / group. *Statistical difference ( P .05 ) between CFU -GM frequency in NOD -SCID mice transplanted with rAd -p53 co -incubated and control CD34 + cells.
and CD42, respectively. In addition, we followed the expression of CD45 (leukocyte ) and CD34, and Thy -1 ( hematopoietic precursors ). [ Anti -CD19, CD8, CD13, CD34, and CD56 were purchased from Becton Dickinson ( Franklin Lakes, NJ ) ; anti -CD38 was purchased from Pharmingen; anti -CD14 and -CD45 were purchased from Coulter ( Fullerton, CA ) ; and anti -glycophorin -A was obtained from Caltag (Burlingame, CA ) .] Samples were stained in subdued light at + 48C for 30 minutes. Unbound antibodies were removed by repeated washing of cells with DPBS -2% FBS. The binding of biotinylated antibodies was revealed by the use of streptavidin -conjugated allophycocyanin (APC ) ( Molecular Probes, Eugene, OR ). Streptavidin APC was added to the cell suspension and incubated in subdued light at 48C for 15 minutes. Cells were washed twice with DPBS -2% FBS to remove unbound antibodies, then fixed with 500 L of 1% paraformaldehyde solution.
Samples were stored at 48C in darkness until analyzed. Data were acquired on a Becton Dickinson FACStar PLUS or FACSCalibur using a 40 -mW argon laser tuned to 488 nm and a 100 -mW krypton laser tuned to 647 nm. Acquisition was performed using CELLQuest and analysis with Attractors software ( Becton Dickinson, San Jose, CA ) . Forward and side scatter were collected on a linear scale, whereas the PE, FITC, and APC signals were collected on a four-decade log scale. Overlaps of emission spectra were electronically compensated. Using the threshold on forward scatter to eliminate debris, 25,000 events were collected from each sample. During analysis, a gate was set on the dot plot of forward and side scatter to include all nucleated cells and to exclude any remaining erythrocyte and cell debris. PE -, FITC -, and APC fluorescence determined the proportion of cells staining positive for each phenotype. A quadrant was applied to acquired events to determine the proportion of dual -stained cells.
Detection of human DNA using the polymerase chain reaction ( PCR ) and Southern blotting DNA was extracted from 10 6 marrow cells from each NOD -SCID mouse in each group using Tri -Reagent ( Molecular Research Center, Cincinnati, OH ) as per manufacturer's instructions. PCR was performed using human -specific Alu primers ( 5 0 -GAGGTGGCAGTGAGCCGAGAT-3 0 and 5 0 -GAGGCTGCAGTGAGCCGTGAT-3 0 ) in a total volume of 40 L containing 1.0 L of genomic DNA, 200 mM dNTP, 5 U of Taq Gold DNA polymerase, and 10Â Taq Gold PCR buffer ( PE Applied Biosystems, Foster City, CA ), 0.5 mM MgCl 2 and 0.5 mM of each Alu primer. Thermal cycler parameters were optimized for the amplification of the human Alu sequence: 4 min /948C followed by 38 cycles of 45 s/948C, 1 min /638C, and 2 min /728C. A final extension at 728C /10 min was added at the end of 38 cycles. The PCR product was separated using 6% TBE pre -cast Novex HIRAI, LAFACE, ROBINSON, ET AL: NOD-SCID RECONSTITUTION polyacrylamide gel (Invitrogen, Carlsbad, CA ) . Staining with ethidium bromide revealed amplified cDNA and was indicative of the presence of human DNA in the DNA extracted from the NOD -SCID marrow cells. To further confirm the human origin of the amplified cDNA, we performed a Southern blot: DNA was transferred to a positively charge nylon membrane (Roche Molecular Chemicals, Palo Alto, CA ) using a Western blot transfer apparatus (Bio -Rad, Hercules, CA ). Gels were transferred overnight in 1Â TBE buffer at 10 V. The membrane was then probed with digoxigenin ( DIG ) -labeled Alu sequences. DIG -conjugated Alu sequences were generated using a DIG PCR Synthesis Kit (Roche Molecular Chemicals ). Specific hybridization was measured using a DIG Luminescence Detection Kit (Roche Molecular Chemicals ) and binding visualized using a Multi-Image Light Cabinet (Alpha Innotech, San Leandro, CA ) .
LDA
Each study with rAd -p53 co-incubated, or control, CD34 + cells was performed three times, each time with different patient samples of G -CSF -mobilized blood. Five NOD -SCID mice were transplanted at each CD34 + cell dose for each of the three studies (total n =15 ). This is sufficient for Poisson-based LDA. 37, 38 LDA was performed based on cellular expression of human phenotypes (flow cytometry ) and expression of human Alu sequences (PCR and Southern blotting ). For the purposes of LDA, all 15 mice in each treatment group were analyzed. Animals were considered ''positive'' with respect to the presence of human cells during flow cytometric analysis if the proportion of fluorescently stained cells exceeded 1 SD from the mean proportion of cells stained in animals receiving no CD34 + cells. With respect to the presence of human DNA, animals were considered ''positive'' if there was evidence of Alu gene amplification by PCR and Southern blotting. In both cases, animals were considered ''negative'' otherwise. Using LDA, the proportion of ''negative'' NOD -SCID mice ( showing no evidence of human cells ) was correlated with the number of CD34 + cells transplanted, and an estimate of the frequency (with 95% confidence interval, CI ) of the progenitor responsible for the persistence of human hematopoiesis in the NOD -SCID mouse 6 weeks after transplantation was generated.
LDA allowed direct comparison of the NOD -SCID repopulating activity of rAd -p53 co-incubated and control CD34 + cells and demonstrated whether co-incubation of CD34 + cells with rAd -p53 particles had any impact on the ability of the transplanted cells to maintain human hematopoiesis 6 weeks after transplantation in the NOD -SCID mouse model.
Secondary transplantation
To investigate whether the repopulating activity responsible for the human cells in the NOD -SCID mice could be transplanted and thereby demonstrate evidence for stem cell self -renewal, we performed secondary transplantation experiments. Recipient NOD -SCID mice were treated intraperitoneally with 50 L of antiasialo GM1 antibody and received 3 Gy total body -irradiation prior to the transplantation of 5Â10 6 marrow cells from primary recipient NOD -SCID mice 6 weeks after transplantation with either 3Â10 5 rAd -p53 co -incubated, or control, CD34 + cells. Five and 11 days after transplantation, mice again received antiasialo GM1 antibody (protocol identical to primary transplantation ). After 2 weeks, recipient NOD -SCID mice were euthanized, and marrow and spleen cells analyzed using flow cytometry for the presence of human cells. Cells were stained with fluorescently labeled antihuman CD34 (PE ) , CD45 ( FITC ), and CD38 (Cy -Chrome ) antibodies.
The presence and expression of the human p53 gene in the NOD -SCID recipients
To investigate the in vivo expression of adenovirusdelivered human p53 gene in the NOD -SCID mice receiving the rAd -p53 co-incubated CD34 + cells, lung and liver tissues were obtained 3 and 10 days, respectively, following the transplantation of 3Â10 5 rAd -p53 co -incubated cells. For comparison, tissue was obtained from nontransplanted NOD -SCID mice. Tissue was removed and immediately cryopreserved. DNA and mRNA were isolated using Trizol Reagent (GibcoBRL ) as per manufacturer's instructions. The presence (DNA ) and expression ( mRNA ) of the adenovirus -delivered human p53 gene were determined quantitatively using PCR and RT-PCR, respectively, and a real -time quantitative PCR system ( TaqMan, PE Biosystems, Foster City, CA ). Quantification was performed in the exponential phase of the PCR, where the relationship between the log of input target DNA quantity and number of PCR cycles to reach an arbitrary level of fluorescence is linear.
39,40
Statistical analyses
In vitro colony -forming cell ( CFU -GM ) data from the marrow of NOD -SCID mice 6 weeks following transplantation with rAd -p53 co -incubated, or control, CD34 + cells were compared using the Student's t test. Differences were considered significant at P .05. LDAs were performed using a Poisson-based limiting dilution calculation. 37, 38, 41 An estimation of the frequency ( with 95% CI ) of hematopoietic progenitors in the rAd -p53 co -incubated, or control, CD34 + cells transplanted, which were responsible for the persistence of human hematopoiesis 6 weeks after transplantation into NOD -SCID mice, was determined.
RESULTS
Assessment of direct acute toxicity following co -incubation of CD34
+ cells with rAd -p53 CD34 + cells from three different stem cell products, isolated at three different times, were used in these studies to demonstrate the reproducibility of these observations. The acute toxicity of a 4 -hour co -incubation with rAd -p53 on the isolated CD34 + cells was compared to co-incubation in medium alone ( control ) using the in vitro CFU -GM assay ( three samples and three CFU -GM plates per sample ). No significant difference between the number of CFU -GM in samples of CD34 + cells co-incubated with rAd -p53 ( 21.8 ±4.2 CFU -GM /10 3 cells plated ) and those incubated with medium alone ( 19.3 ± 4.0 CFU -GM /10 3 cells plated ) was observed. These data suggest that there was no acute toxicity associated with co -incubation of rAd -p53 with isolated CD34 + cells. 
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The presence of human p53 gene and p53 gene expression Following co-incubation with rAd -p53, or medium, the CD34 + cells were injected into sublethally irradiated NOD -SCID mice. In addition, to eradicate NK cells, the mice received multiple injections of antiasialo GM1 ( as detailed in Materials and Methods ). rAd -p53 particles were not removed prior to injection, and the expression of rAddelivered human p53 gene in liver and lung tissue from the mice was examined 3 and 10 days after injection. Data are presented as the number of copies of the human p53 gene ( DNA and mRNA ) per milligram of lung or liver tissue ( Table 1) . No human p53 DNA or p53 mRNA could be detected in lung and liver tissues from nontransplanted NOD -SCID mice.
Investigating the impact of rAd -p53 co -incubation with CD34 + cells on NOD -SCID repopulation
Six weeks after transplantation of rAd -p53 co-incubated or control human CD34 + cells into the sublethally irradiated NOD -SCID recipient mice, the proportion of humanderived CFU -GM was measured in the marrow using human -specific growth factors. In the presence of the species-specific growth factors (rhuIL -3 and rhuGM -CSF ) , a background of 6 ± 1 CFU -GM /10 6 marrow cells was observed in NOD -SCID mice transplanted with only lethally irradiated ( 15 Gy ) human marrow ''carrier'' cells. In all groups ( mice receiving rAd -p53 co -incubated or control CD34 + cells ), a significant increase in the frequency of CFU -GM was observed relative to the mice receiving lethally irradiated human ''carrier'' cells alone (Fig 1 ) + cells were co -incubated with rAd -p53, the proportion of the NOD -SCID marrow cells staining positively for each of the human phenotypes increased with increasing numbers of CD34 + cells transplanted. A graphical representation of an LDA plot is shown in Figure 2 . ( Data presented were calculated as previously described. 37 ) Figure 6 . Six weeks after receiving 3Â10 3 -3Â10 5 rAd -p53 co -incubated, or control, human CD34 + cells, NOD -SCID bone marrow was isolated and evidence of human -derived cells sought by PCR, using a human -specific Alu oligonucleotide, and Southern blotting and probing with labeled Alu oligonucleotide sequences. The incidence of human cells persisting in the NOD -SCID mice increased with increasing numbers of human CD34 + cells injected. LDA of the data allowed the estimation and comparison of the frequency of hematopoietic progenitors in the transplanted CD34 + samples. LDA estimates of frequencies of the transplanted progenitor frequency responsible for the persistence of human hematopoiesis in the NOD -SCID mice 6 weeks after transplantation are shown graphically, and the results of the calculated frequency and confidence interval are shown in the figure insert. These data suggest that co -incubation with rAd -p53 has no significant impact on the frequency of progenitor cells responsible for the persistence of human cells in NOD -SCID recipient mice.
Cancer Gene Therapy, Vol 8, No 12, 2001 These data suggest that rAd -p53 co-incubation does not significantly impact the ability of the transplanted human G -CSF -mobilized CD34 + cells to maintain human hematopoiesis 6 weeks after transplantation. LDA 37, 38, 41 of the human hematopoietic subpopulations present 6 weeks after transplantation relative to the number of human CD34 + cells transplanted allows an estimate of the NOD -SCID repopulating activity in the transplanted sample ( rAd -p53 co-incubated, or control, CD34 + cells) to be made. This analysis provides a quantitative assessment of the potential impact of rAd -p53 co-incubation on the SRA of the transplanted CD34 + cells. Data are presented (Fig 3) as a frequency of cell precursors ( with 95% CI ) in the transplanted CD34
+ cells (rAd -p53 co-incubated, or control ) . An overlapping 95% CI indicates that there is no significant difference in the precursor frequencies. These data suggest that rAd -p53 co -incubation does not significantly impact the SRA of G -CSF -mobilized human CD34 + cells. Using a human -specific Alu gene sequence, we performed PCR and Southern blot analysis on samples of DNA extracted from NOD -SCID marrow cells 6 weeks after transplantation with rAd -p53 co -incubated, or control, CD34 + cells. During the development of this protocol, we identified PCR conditions that allowed us to identify the DNA from one human cell in the presence of the DNA from 10 6 mouse spleen cells (Fig 4) . For LDA, a mouse was considered ''positive'' if evidence of human -specific Alu sequences was found by PCR and Southern blot analysis. During sample analysis, the gels were blotted and probed with labeled Alu oligonucleotide sequences to increase the sensitivity. To illustrate the appearance of Alu oligonucleotide -probed Southern blots, a composite of several representative scanned images is presented in Figure 5 . 5 human control ( no rAd -p53 coincubation ) CD34 + cells.] Smearing is a consequence of the polymorphisms and concatamers of Alu sequences that occur within the human genome. Samples were considered ''negative'' for LDA if no evidence of human -specific Alu sequences was evident by PCR and Southern blotting ( Table 1 ) .
We observed an increase in the frequency of ''positive'' samples with increasing numbers of rAd -p53 co -incubated, or control, CD34 + cells transplanted. LDA of the humanspecific Alu sequence data allowed us to determine the impact of co-incubation with rAd -p53 on the hematopoietic reconstituting potential of the transplanted cells. LDA of the frequency of cells responsible for the persistence of human cells in the NOD -SCID mouse 6 weeks after transplantation is shown graphically in Figure 6 . An LDA estimate of one NOD -SCID repopulating cell (SRC ) in 94,170 (95% CI: 56,391 -157,256 ) transplanted rAd -p53 co -incubated CD34 + cells and one SRC in 50,747 (95% CI: 29,662 -86,819 ) transplanted control CD34 + cells was made. These results extend the flow cytometric data presented and suggest that the co -incubation of isolated human CD34 + cells with rAd -p53 does not affect the SRA of the transplanted cells to maintain human hematopoiesis for 6 weeks in the NOD -SCID mouse model.
Determination of stem cell self -renewal by secondary transplantation
Six weeks after transplantation with 3Â10 5 rAd -p53 coincubated, or control, CD34
+ cells, 5Â10 6 chimeric ( mouse /human ) marrow cells were harvested from the primary NOD -SCID recipient mice and transplanted into Figure 7 . To determine whether stem cell self -renewal was occurring in the NOD -SCID mice receiving the rAd -p53 co -incubated, or control, human CD34 + cells, secondary transplantation was performed. Evidence of human cells in the marrow and spleen of the secondary recipients was sought by flow cytometry. Human -derived cells ( CD34 + , CD45 + , and CD38 + ) were detected in the marrow and spleens of all the secondary recipients. These data indicate that human -derived NOD -SCID repopulating activity was present in tissue transplanted from primary recipients receiving either rAd -p53 co -incubated, or control, CD34 + cells. With one exception ( humanderived CD45 + cells in the bone marrow ) , there was no significant difference between the proportion of human -derived cells in the bone marrow ( a ) and spleen ( b ) of the secondary recipients receiving marrow cells from primary NOD -SCID mice transplanted with either rAd -p53 co -incubated, or control, human CD34 + cells. Data presented as mean ± SEM. *Statistical difference ( P < .05 ) between secondary NOD -SCID recipient mice transplanted with chimeric ( mouse / human marrow ) from primary recipient NOD -SCID mice receiving rAd -p53 co -incubated, or control, CD34 + cells.
Cancer Gene Therapy, Vol 8, No 12, 2001
HIRAI, LAFACE, ROBINSON, ET AL: NOD-SCID RECONSTITUTION sublethally irradiated, antiasialo GM1 antibody -treated, secondary recipient NOD -SCID mice. After 2 weeks, secondary recipient NOD -SCID mice were sacrificed, and evidence of the presence of human cells in the marrow and spleen sought was assessed using flow cytometry. Humanderived cells (CD34 + , CD45 + , and CD38 + ) were detected in the spleen and marrow of all the secondary recipients, indicating that human -derived SRA was present in tissue transplanted from primary recipients receiving either rAdp53 co -incubated, or control, CD34 + cells. With one exception [human -derived CD45 + cells in the bone marrow, 5.9± 0.2% ( rAd -p53 ) vs 9.0 ± 0.9% (control ) ] , there was no significant difference between the proportion of human -derived cells in the bone marrow ( Fig 7a) [ CD34 + : 2.1 ± 1.0% (rAd -p53 ) vs 4.9 ± 1.5% ( control ) and CD38 + : 0.10 ± 0.02% ( rAd -p53 ) vs 0.15 ± 0.02% (control ) ] and spleen (Fig 7b) [CD34 + : 0.8 ± 0.3% (rAd -p53) vs 1.4 ± 0.4% ( control ) , CD45 + : 4.8± 0.5% (rAd -p53 ) vs 5.7 ± 0.5% ( control ) and CD38 + : 0.3 ± 0.1% ( rAd -p53 ) vs 0.4 ± 0.1% (control ) ] of the secondary recipients receiving marrow cells from primary NOD -SCID mice transplanted with either rAd -p53 co-incubated ( n=5) or control ( n =4 ) human CD34 + cells. These data suggest that co -incubation with rAd -p53 does not significantly impact the self -renewal capacity of G -CSF -mobilized human CD34 + cells.
DISCUSSION
A number of approaches for the ex vivo purging of tumor cells from stem cell products have been used or are under development. 42 While able to reduce tumor cell contamination by one to three logs, such approaches are often associated with delayed hematopoietic and immunologic reconstitution following transplant. 43 -54 Further, the efficacy of chemotherapy-based antitumor therapies is significantly reduced in tumors containing mutations in p53, a frequent mutation observed in tumor cells. 55 However, such tumor cells may be susceptible to adenovirus -delivered wild -type p53. The re -introduction of wild -type p53 can suppress growth and/ or induce apoptosis in tumor cells. 33, 56, 57 Here we report that tumor cell purging using coincubation of human CD34 + cells with a replicationdeficient, recombinant adenovirus containing the wild -type p53 gene (rAd -p53) at a targeted clinical dose can be achieved without significant loss of stem cell activity, as measured by SRA. SRA provides a stringent, preclinical assay with which to assess the in vivo hematopoietic impact of therapies that manipulate stem cell products. SRA and the use of LDA provide sensitive and quantitative measures of stem cell activity. Our protocol was designed to minimize handling of the stem cell products and used a co -incubation with rAd -p53 for a period of 4 hours at 378C. 18 The concentration of vector selected ( 2Â10 11 rAd -p53 particles / mL ) was previously determined to provide a six -log tumor cell reduction in cytokine -mobilized stem cell products. 18 The studies presented here have enabled us to quantify the effect of co -culturing isolated, cytokine -mobilized CD34 + cells with clinically relevant concentrations of rAd -p53 and to determine the effect of this treatment on subsequent engraftment and multilineage hematopoietic reconstitution of NOD -SCID recipients. Here we provide evidence that SRA, multipotency, and self -renewal of stem cell products are not compromised by co -incubation with rAd -p53 at targeted clinical levels. These data significantly extend research efforts on the purging of tumor cells from HSC products and include the first use of an SRA model using isolated, cytokine-mobilized human CD34 + cells to assess the toxicity of a tumor cell purging protocol.
Reported estimates of the frequency of SRA of human CD34 + cells vary markedly. van der Loo et al 58 estimate the frequency of SCID repopulating cells (SRC ) in human G -CSF -mobilized blood at one SRC in 1.7Â10
6 CD34 + cells and cautions that reported frequencies should only be used for relative comparisons. Methods used to estimate the frequency of SRA, the mouse models used, and differences in the sensitivities of flow cytometry and Southern blotting each adds to the variation between laboratories. In our PCR and Southern blot analyses, we used an Alu sequence, which significantly increased our ability to detect human cells in the human /NOD -SCID chimeric mice. The sensitivity of our PCR and Southern blot analysis was increased when compared with our flow cytometric analysis and is also potentially increased relative to other studies of SRA. + cells (LDA of PCR and Southern blot data ). We were able to demonstrate that co-incubation with rAd -p53 did not significantly impact the SRA of the isolated G -CSF -mobilized CD34 + cells. The majority of SRA data have been reported for human cord blood. The frequency of SRC is reported to be higher in cord blood than in bone marrow, or G -CSF -mobilized blood, 59 23 presumably by receptor-mediated endocytosis. 63 In contrast, adenovirus infection of HSC products occurs more slowly and at a significantly lower frequency, resulting in a decrease in adenovirus infection. 17 -19,22 ,57 CD34 + cells have been shown to be approximately 4000 -fold less readily transduced by adenoviral vectors expressing reporter genes than tumor cells. 17, 22, 23 This selectivity may be uniquely exploited in the purging of tumor cells from stem cell products and we have previously shown that the conditions used for these studies can result in six -log tumor cell killing by rAdp53. 18 This finding suggests that an rAd -p53 tumor cell purging protocol may provide a two-to four-log increase in efficacy when compared to conventional strategies. 25 Another advantage to the use of an rAd -p53 tumor cell purging strategy includes the absence of additional steps following transplantation. Several transgene strategies have been used for tumor cell purging. Examples include thymidine kinase ( TK ) , cytosine deaminase (CD ), and p53. 17,18,20,22 -24,55,63 In contrast to the use of the p53 gene, the use of TK or CD may require additional co -culture of the stem cell product, or direct injection of the patient with ganciclovir, or 5-fluorocytosine for 7-10 days, limiting the potential use of this approach in the clinic. 13, 14, 24 The apparent absence of detrimental effects of co -incubation of stem cell products with rAd -p53 as a purging strategy reported here is an encouraging finding and consistent with our previous experience. 17, 18, 27, 28 In contrast to the studies with flow cytometry and PCR using an LDA, studies examining the formation of CFU -GM were uninformative. In all the groups of mice, whether receiving rAd -p53 co-incubated or control CD34 + cells, a significant increase in the frequency of CFU -GM was observed relative to the mice receiving lethally irradiated human carrier cells. However, despite the 100 -fold variation in the number of rAd -p53 co-incubated or control human CD34 + cells transplanted, there was no association between the number of human CD34 + cells injected and the proportion of human -derived CFU -GM observed in the marrow of the recipient NOD -SCID mice. Thus, in contrast to the flow cytometric analysis and PCR analysis, this suggests a lack of sensitivity by the CFU -GM assay for the assessment of an effect by co -culture with rAd -p53 on human CD34
+ cells prior to transplantation. The absence of any correlation between the number of human CD34 + cells transplanted and the number of human -derived CFU -GM observed is consistent with CFU -GM representing a relatively mature, lineage-committed component of the hematopoietic system. The proliferation of CFU -GM is more a measure of the physiological demands put on the hematopoietic system for the production of mature hematopoietic cells rather than the number of stem cells present. This conclusion is reinforced by the observations of Wang et al 59 who, while not transplanting different numbers of human cells, report considerable interanimal variation in the number of human -derived colony -forming cells ( CFC ) in the marrow of otherwise identically transplanted animals (1Â10 6 human cord blood mononuclear cells injected and marrow assayed for the presence of human -derived CFC after 6 weeks) . Further, there was a background of 6 ± 1 CFU -GM / 10 6 marrow cells from the NOD -SCID mice, which have been transplanted with only lethally irradiated ( 15 Gy ) human marrow ''carrier'' cells. Whether these colonies were of human or murine origin was not determined; however, both human IL -3 and human GM -CSF share little amino acid sequence homology with their murine counterparts. Consistent with this lack of homology, neither factor has activity on murine cells. These data suggest that either (a ) human progenitors with SRA survived the 15 -Gy irradiation and were injected in the 2Â10 6 ''carrier'' cells administered to each mouse and subsequently gave rise to human -derived CFU -GM 6 weeks after transplantation, or (b ) proliferation of a limited number of murine colony -forming cells occurred despite the absence of appropriate colony -stimulating activity, which can be due to growth factors in FBS and /or the presence of murine stromal cells. 64 We conclude from these three analyses that the use of the PCR assay, based on Alu sequences, which is described here for the first time, provides the greatest sensitivity for the detection of human cells, although flow cytometry not only provides evidence for the presence of SRA, but also the multipotentiality and linearity of the reconstituting cells.
In addition to the direct purging of tumor cells ex vivo during the co-incubation period, another potential benefit to the use of rAd -p53 relates to the presence of free virus particles in the transplanted stem cell product. Transplanted free rAd -p53 particles may be capable of transducing residual tumor cells in the host. In this study, the rAd -p53 co -incubated CD34 + cells were not washed prior to infusion in the NOD -SCID hosts. Evidence for the capacity of transplanted free adenovirus to transduce cells in vivo was obtained by measuring wild -type human p53 DNA and the expression of the wild -type human p53 gene ( by RT-PCR ) in lung and liver tissues of transplanted NOD -SCID mice, 3 and 10 days after transplantation. Human p53 expression was detected in almost all samples that were analyzed, suggesting that residual tumor cells in the host may be transduced with wild -type p53. These findings suggest that this may provide an additional mechanism of rAd -p53-associated anticancer treatment.
We conclude that the NOD -SCID mouse engraftment model provides a highly sensitive and effective in vivo preclinical assay to assess the impact of novel tumor cell purging procedures on the capacity of stem cell products to reconstitute the hematopoietic system of recipients following transplantation. These data suggest that the co -incubation of stem cell products with rAd -p53 does not significantly impact stem cell activity and potentially provides a highly effective method for purging tumor cells from stem cell products prior to transplantation.
